BWVI Blue Water Ventures International

BWVI and Its Branding Partner SponsorsOne Announce Their New Campagn for 2019 Featuring Shipwreck Jewelry By Bradford James and Benefiting The Thirst Project

BWVI and Its Branding Partner SponsorsOne Announce Their New Campagn for 2019 Featuring Shipwreck Jewelry By Bradford James and Benefiting The Thirst Project

Jacksonville FL, Jan. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Blue Water Ventures International, Inc. (OTCPK: BWVI) and its branding partner SponsorsOne are proud to announce the first of many humanitarian projects that BWVI will donate a percentage of the sales from the recent launch of its treasure jewelry line.  .  In this case the benefit goes to Chester See’s work with The Thirst Project building water wells in southern Africa.  (see video link below)

Working with SponsorOne has resulted in a multi-faceted campaign to market our line of Treasure Jewelry around the world and produce revenue.  The efforts are designed to elevate the BWVI brand through a network of social media efforts through established global influencers large and small.  

Keith Webb, President of Blue Water Ventures states, “We are very excited about the exclusive jewelry line that Bradford James has designed with Blue Water treasure and feel that the team at SponsorsOne have put together a worthy project for BWVI to be a part of.”

“It’s an honor and a privilege to be working with the amazing recoveries of Blue Water Ventures in conjunction with Chester See’s support of The Thirst Project,” said Guy Zajonc, President of Sponsors One Media.  “I believe my creative team has captured all the adventure of Blue Water couple with the good works of Chester See and The Thirst Project for the world to see and enjoy.”  

About Blue Water Ventures International, Inc.: 

The Company is engaged in the business of conducting archaeologically-sensitive recoveries of cargo and artifacts from shipwrecks. Its operations to date have focused on shallow water search and recovery projects in less than 150 feet of water. The Company is now expanding its focus to include deep-water salvage of historic and modern-day shipwrecks. For more information go to 

About SponsorsOne:

SponsorsOne is the leader in the next evolution of digital marketing through storytelling and digital-commerce with the SponsorCoin platform and its highly scalable digital – smart contract based digital-currency. Combined, this allows Brands to build and manage exclusive and highly engaged communities of micro-influencers within the social realm. The SponsorCoin platform provides for data-driven marketing campaigns that will change the way brands connect to their customers and to compensate the consumer for authentic engagement using the SponsorCoin digital currency. SponsorCoin is a tool for brands to inspire real movements around their products and services in which their most valuable customers become their best salespeople, producing far higher ROI than current social media advertising methods.  Go to: 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to certain risks and uncertainties including, but not limited to: ability to further strengthen our balance sheet, ability to raise funding for continued operations, ability to successfully and profitably locate additional wrecks and cargo, ability to establish ownership, and other factors. Therefore, actual results may differ materially from those indicated or implied by such forward-looking statements. Except as required by law, the Company disclaims any obligation to publicly update such statements.



Contact:

Blue Water Ventures International, Inc.

Keith Webb
904-215-7601
 
EN
09/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Water Ventures International

 PRESS RELEASE

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick...

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, hosted Rick Doblin, the Founder and Preside...

 PRESS RELEASE

Psycheceutical Bioscience, Inc. Announces Observational Research Resul...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical creamPatients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge tec...

 PRESS RELEASE

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trial...

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical"...

 PRESS RELEASE

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for To...

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (F...

 PRESS RELEASE

Psycheceutical Bioscience Provisional Patent Application for Novel Ket...

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD). The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch